NurExone Biologic Inc.
NRXBF
$0.40
$0.000.40%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.61% | -26.59% | -54.35% | -52.62% | -50.39% |
| Total Depreciation and Amortization | 75.22% | 117.65% | 248.98% | 189.80% | 169.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.71% | 32.53% | 49.77% | 94.66% | 80.31% |
| Change in Net Operating Assets | 1,460.00% | 140.30% | 100.87% | 192.81% | 98.96% |
| Cash from Operations | -7.98% | 7.71% | -33.97% | -22.60% | -23.05% |
| Capital Expenditure | 94.32% | 91.53% | 86.27% | -3.53% | -42.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -92.31% | -92.31% | -139.13% |
| Cash from Investing | 94.43% | 91.64% | 86.15% | -7.04% | -56.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.00% | 26.67% | 38.71% | 44.12% | 10.71% |
| Issuance of Common Stock | 133.50% | -0.43% | 6.00% | -27.74% | -56.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -214.23% | -73.28% | -25.26% |
| Cash from Financing | 132.18% | -0.75% | -35.43% | -29.50% | -56.84% |
| Foreign Exchange rate Adjustments | 179.90% | 198.27% | -462.50% | -414.71% | -9,850.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.57% | 804.40% | -211.59% | -176.88% | -259.99% |